These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 6736272)

  • 21. Plasma haloperidol levels and clinical response: confounding variables.
    Mavroidis ML; Garver DL; Kanter DR; Hirschowitz J
    Psychopharmacol Bull; 1985; 21(1):62-5. PubMed ID: 3983340
    [No Abstract]   [Full Text] [Related]  

  • 22. Depot haloperidol treatment in outpatients with schizophrenia on monotherapy: impact of CYP2D6 polymorphism on pharmacokinetics and treatment outcome.
    Panagiotidis G; Arthur HW; Lindh JD; Dahl ML; Sjöqvist F
    Ther Drug Monit; 2007 Aug; 29(4):417-22. PubMed ID: 17667795
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Negative correlation between alpha-1-acid-glycoprotein plasma level and response to haloperidol in the acute treatment of schizophrenia.
    Levinson I; Levine S
    Biol Psychiatry; 1995 Aug; 38(3):198-200. PubMed ID: 7578667
    [No Abstract]   [Full Text] [Related]  

  • 24. Haloperidol plasma/red blood cell ratios and clinical efficacy.
    Neborsky R; Janowsky DS; Perel J; Munson E; Depry D
    Psychopharmacol Bull; 1982 Oct; 18(4):17-20. PubMed ID: 7156285
    [No Abstract]   [Full Text] [Related]  

  • 25. Beneficial antipsychotic effects of allopurinol as add-on therapy for schizophrenia: a double blind, randomized and placebo controlled trial.
    Akhondzadeh S; Safarcherati A; Amini H
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Feb; 29(2):253-9. PubMed ID: 15694232
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The impact of omega-3 fatty acids, vitamins E and C supplementation on treatment outcome and side effects in schizophrenia patients treated with haloperidol: an open-label pilot study.
    Sivrioglu EY; Kirli S; Sipahioglu D; Gursoy B; Sarandöl E
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1493-9. PubMed ID: 17688987
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of varying haloperidol plasma levels on negative symptoms in schizophrenia and schizoaffective disorder.
    Volavka J; Cooper TB; Czobor P; Meisner M
    Psychopharmacol Bull; 1996; 32(1):75-9. PubMed ID: 8927679
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dose and blood levels of haloperidol in treatment of mania.
    Rifkin A; Karajgi B; Doddi S; Cooper T
    Psychopharmacol Bull; 1990; 26(1):144-6. PubMed ID: 2371369
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Haloperidol and thioridazine drug levels and clinical response in schizophrenia: comparison of gas-liquid chromatography and radioreceptor drug level assays.
    Smith RC; Baumgartner R; Burd A; Ravichandran GK; Mauldin M
    Psychopharmacol Bull; 1985; 21(1):52-8. PubMed ID: 3983338
    [No Abstract]   [Full Text] [Related]  

  • 30. Comparative efficacy of red cell and plasma haloperidol as predictors of clinical response in schizophrenia.
    Smith RC; Baumgartner R; Shvartsburd A; Ravichandran GK; Vroulis G; Mauldin M
    Psychopharmacology (Berl); 1985; 85(4):449-55. PubMed ID: 2862652
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Haloperidol and reduced haloperidol in saliva and blood.
    Dysken MW; Johnson SB; Holden L; Kuskowski M; Ofstehage J; Skare S; Vatassery G
    J Clin Psychopharmacol; 1992 Jun; 12(3):186-90. PubMed ID: 1629385
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical response and plasma haloperidol levels in schizophrenia.
    Mavroidis ML; Kanter DR; Hirschowitz J; Garver DL
    Psychopharmacology (Berl); 1983; 81(4):354-6. PubMed ID: 6419263
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlation of haloperidol levels between saliva and plasma of acutely ill schizophrenic patients.
    Jain T; Bhandari A; Ram V; Sharma S; Parakh M; Parakh MC
    Clin Biochem; 2011 Jun; 44(8-9):675-80. PubMed ID: 21458435
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Comparison of the therapeutic effects between haloperidol and insulin coma in schizophrenia and optimal blood levels of haloperidol].
    Shu L
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1987 Feb; 20(1):43-8. PubMed ID: 3304870
    [No Abstract]   [Full Text] [Related]  

  • 35. Does a therapeutic window for plasma haloperidol exist?: Preliminary Chinese data.
    Potkin SG; Shen YC; Zhou DF; Pardes H; Shu L; Phelps B; Poland R
    Psychopharmacol Bull; 1985; 21(1):59-61. PubMed ID: 3983339
    [No Abstract]   [Full Text] [Related]  

  • 36. Fluphenazine plasma levels and clinical response.
    Mavroidis ML; Kanter DR; Hirschowitz J; Garver DL
    J Clin Psychiatry; 1984 Sep; 45(9):370-3. PubMed ID: 6381472
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Measurement of haloperidol reductase activity in red blood cells and reduced haloperidol/haloperidol ratios in plasma in oriental psychiatric patients.
    Shibasaki M; Someya T; Kato T; Noguchi T; Ishida N; Takahashi S
    Prog Neuropsychopharmacol Biol Psychiatry; 1990; 14(6):941-7. PubMed ID: 2277853
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ketone reductase activity and reduced haloperidol/haloperidol ratios in haloperidol-treated schizophrenic patients.
    Huang HF; Jann MW; Tseng YT; Chung MC; Chien CP; Chang WH
    Psychiatry Res; 1995 Jul; 57(2):101-8. PubMed ID: 7480377
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of prolactin concentrations between haloperidol and bromperidol treatments in schizophrenic patients.
    Yasui-Furukori N; Kondo T; Suzuki A; Mihara K; Kaneko S; Otani K
    Prog Neuropsychopharmacol Biol Psychiatry; 2002 Apr; 26(3):575-8. PubMed ID: 11999910
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Haloperidol dose, plasma levels, and clinical response: a double-blind study [proceedings].
    Ericksen SE; Hurt SW; Chang S
    Psychopharmacol Bull; 1978 Apr; 14(2):15-6. PubMed ID: 349597
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.